EUCTR2018-004815-33-GB进行中（未招募）1 期
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults with Hypoparathyroidism. - PaTH Forward
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females aged =18 years
- •2. Subjects with postsurgical chronic HP or auto-immune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is established based on hypocalcemia in the setting of inappropriately low serum parathyroid hormone (PTH) levels.
- •3. On a stable dose* for at least 12 weeks prior to Screening of:
- •- =0.25 µg BID of calcitriol (active vitamin D) or =0.5 µg BID or =1.0 µg daily of alfacalcidol (active vitamin D) and
- •- =400 mg BID calcium citrate or carbonate
- •If subject has a history of hypercalcemia on such doses, subject may be taking <0.25 µg BID of calcitriol, <0.5 µg BID or < 1.0 µg daily of alfacalcidol, or <400 mg BID of calcium citrate or carbonate, with approval of Medical Monitor/Medical Expert
- •*Does not preclude occasional (<3/week) rescue doses of active vitamin D and/or calcium for symptomatic hypocalcemia
- •4. Optimization of supplements prior to randomization to achieve the target levels of:
- •- 25(OH) vitamin D levels of 30-70 ng/mL (75-175 pmol/mL) and
- •- Magnesium level within the normal range* and
- •- Albumin-adjusted or ionized serum calcium (sCa) level in the lower half of the normal range
- •*If subject has a history of inability to be successfully managed within the normal range for magnesium level, a level slightly below the normal range is acceptable with approval of the Medical Monitor/Medical Expert
- •5. BMI 17-40 kg/m2 at Visit 1
- •6. If =25 years of age, radiological evidence of epiphyseal closure based on x-ray of non-dominant wrist and hand
- •7. eGFR >30 mL/min/1.73m2 during Screening
- •8. Thyroid-stimulating hormone (TSH) within normal laboratory limits within the 12 weeks prior to Visit 1; if on suppressive therapy for thyroid cancer, TSH level must be =0.2 µIU/mL
- •9. If treated with thyroid hormone replacement therapy, the dose must be stable for at least 12 weeks prior to Visit 1
- •10. Able to perform daily subcutaneous self-injections of study drug (or have a designee perform injection) via a pre-filled injection pen
- •11. Written, signed, informed consent of the subject
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Known activating mutation in the calcium-sensing receptor (CaSR) gene
- •2. Impaired responsiveness to PTH (pseudohypoparathyroidism) which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia
- •3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP, such as active hyperthyroidism; Paget’s disease; hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus; severe and chronic cardiac, liver, or renal disease; Cushing syndrome; rheumatoid arthritis; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer or basal cell skin cancer); parathyroid carcinoma within 5 years prior to Screening;
- •acromegaly; multiple endocrine neoplasia types 1 and 2
- •4. Use of loop diuretics, phosphate binders (other than calcium carbonate/calcium citrate), digoxin, lithium, methotrexate, or systemic corticosteroids (other than replacement therapy)
- •5. Use of thiazide diuretic within 4 weeks prior to the Screening 24-hour urine collection or the first dose adjustment of SOC during Screening
- •6. Use of PTH-like drugs (whether commercially available or through participation in an investigational trial) including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein within 12 weeks prior to Visit 1
- •7. Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (> 0.5 mg/day), strontium, or cinacalcet hydrochloride within 12 weeks prior to Visit 1
- •8. Use of bisphosphonates (oral or IV) or denosumab within 2 years prior to Visit 1
- •9. Non-hypocalcemic seizure disorder with a history of a seizure within 26 weeks prior to Visit 1
- •NOTE: History of seizures that occur in the setting of hypocalcemia is not exclusionary
- •10. Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton
- •11. Pregnant or lactating women.
- •NOTE: Highly effective contraception (see Appendix 7) is required for sexually active women of childbearing potential during the trial and for 2 weeks after the last dose of study drug, and pregnancy testing will be performed throughout the trial. Sexually active women of childbearing potential who are unwilling to use highly effective contraception are excluded from the trial.
- •12. Diagnosis of drug or alcohol dependence within 3 years prior to Visit 1
- •13. Disease processes that may adversely affect gastrointestinal absorption including but not limited to short bowel syndrome, bowel resection, gastric bypass, tropical sprue, active celiac disease, active ulcerative colitis, gastroparesis, AIRE gene mutations with malabsorption, and active Crohn’s disease
- •14. Chronic or severe cardiac disease within 26 weeks prior to Visit 1 including but not limited to congestive heart failure, myocardial infarction, QTcF >430 msec (males) or
- •>450 msec (females), severe or uncontrolled arrhythmias, bradycardia (resting heart rate
- •<50 beats/minute), symptomatic hypotension, systolic BP <80 mm Hg or diastolic
- •<40 mm Hg, or poorly controlled hypertension (systolic BP >150 mm Hg or diastolic
- •>95 mm Hg)
- •15. Cerebrovascular accident within 5
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitisActive ulcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003349-41-DESublimity Therapeutics (Hold Co) Ltd.380
进行中（未招募）
1 期
To evaluate the efficacy of M281 injection for the treatment of patients with Myasthenia gravis, a neuromuscular diseaseTreatment of MG, with an initial focus on patients with gMG treated with M281 injection and evaluation of the expected reduce of circulating levels of antibodies by blocking IgG recycling, including the pathogenic autoantibodies that cause MG, and to ameliorate manifestations of the disease.MedDRA version: 20.0Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002247-28-ESMomenta Pharmaceuticals, Inc.68
招募中
1 期
VTX958 for the Treatment of Moderately to Severely Active Crohn’s DiseaseEUCTR2022-003365-38-SKVentyx Biosciences, Inc.93
进行中（未招募）
1 期
VTX958 versus Placebo for the Treatment of Active Psoriatic ArthritisActive Psoriatic ArthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2022-003056-14-HUVentyx Biosciences, Inc195
进行中（未招募）
1 期
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque PsoriasisEUCTR2019-004901-28-HUEvelo Biosciences Inc.225